Recent Articles

Genetic Ablation of KRAS in Pancreas Cancer: When an Essential Oncogene Isn’t

| January 5, 2018 | 0 Comments

Genetic Ablation of KRAS in Pancreas Cancer: When an Essential Oncogene Isn’t Of all cancers, pancreatic cancers are most dependent on mutant KRAS. However, many pancreatic cancer cell lines survive loss of their mutant KRAS genes. The adaptations these lines make provide opportunities for treating these deadly cancers.See Original Article What Do We Mean By […]

Continue Reading

Unique Trial Aims to Decrease Early Deaths in Patients with Rare Leukemia

| January 3, 2018 | 0 Comments

Unique Trial Aims to Decrease Early Deaths in Patients with Rare Leukemia In a unique clinical trial, a group of oncologists with experience treating acute promyelocytic leukemia are making themselves available around the clock to help clinicians at hospitals across the country treat their APL patients.See Original Article

Continue Reading

Fusobacterium May Help Colorectal Cancer Grow and Spread

| December 29, 2017 | 0 Comments

Fusobacterium May Help Colorectal Cancer Grow and Spread Fusobacterium, found in the stomach and intestines, may help fuel the growth of colorectal cancer and metastases. In a mouse model of colorectal cancer, using antibiotics to kill these bacteria slowed tumor growth.See Original Article

Continue Reading

New on NCI’s Websites for December 2017

| December 27, 2017 | 0 Comments

New on NCI’s Websites for December 2017 NCI periodically provides updates on new websites and other online content of interest to the cancer community.See Original Article

Continue Reading

Genomic Profiling Tests Cleared by FDA Can Help Guide Cancer Treatment, Clinical Trial Enrollment

| December 21, 2017 | 0 Comments

Genomic Profiling Tests Cleared by FDA Can Help Guide Cancer Treatment, Clinical Trial Enrollment The FDA has recently approved two tests to identify genetic alterations in tumors. One of the tests can be used to identify patients who may be candidates to receive specific targeted therapies.See Original Article

Continue Reading

Brentuximab Vedotin Approved for Two Rare Lymphomas

| December 19, 2017 | 0 Comments

Brentuximab Vedotin Approved for Two Rare Lymphomas FDA has approved brentuximab vedotin (Adcetris®) for the treatment of adults who have been treated previously for either primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides, two rare lymphomas that start as rashes on the skin.See Original Article NCI: Taking Risks to Advance Science Norman Sharpless, […]

Continue Reading

Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma

| December 12, 2017 | 0 Comments

Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma The FDA has granted accelerated approval to acalabrutinib (Calquence®) for the treatment of adults with mantle cell lymphoma whose cancer has progressed after receiving at least one prior therapy.See Original Article

Continue Reading

With Advances in Cancer Immunotherapy, Scientists Discuss Need to Develop New Mouse Models

| December 8, 2017 | 0 Comments

With Advances in Cancer Immunotherapy, Scientists Discuss Need to Develop New Mouse Models A recent NCI symposium focused on developing new and better mouse models for testing treatments that harness the immune system against cancer. See Original Article

Continue Reading

New Treatment Target Identified for Diffuse Large B-Cell Lymphoma

| December 7, 2017 | 0 Comments

New Treatment Target Identified for Diffuse Large B-Cell Lymphoma NCI researchers have identified new therapeutic targets for diffuse large B-cell lymphoma. Drugs that hit these targets are under clinical development and the researchers hope to begin testing them in clinical trials of patients with DLBCL.See Original Article October Spotlight: Breast Cancer Disparity Highlights CRCHD recognizes […]

Continue Reading

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer

| December 6, 2017 | 0 Comments

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer FDA has approved alectinib (Alecensa) as a first-line treatment option for patients with advanced non-small cell lung cancer that is ALK positive. Alectinib is the third ALK inhibitor to be approved in this setting.See Original Article Special Spotlight: 2014 AACR Conference: The Science of Cancer […]

Continue Reading